Multiple clinical vertebral fractures following denosumab discontinuation

Osteoporosis International

Volumn 27, Issue 5, 2016, Pages 1929-1930

  Anastasilakis, A D ^a   Makras, P ^b  

^a 424 General Army Hospital   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; PEPTIDE; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; BACKACHE; BONE TURNOVER; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MIDDLE AGED; MULTIPLE FRACTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PRIORITY JOURNAL; REBOUND; SPINE FRACTURE; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; SPINAL FRACTURES;

EID: 84951733987     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3459-5     Document Type: Letter

References (3)

1. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2015) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int
2. Brown JP, Roux C, Törring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–752
3. Bone HG, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Dakin P, Wagman, Papapoulos S. Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial. Annual meeting of the American Society for Bone and Mineral Research (ASBMR), October 9–12, 2015, Seattle, USA